These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28546261)

  • 1. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.
    Dehbi HM; Royston P; Hackshaw A
    BMJ; 2017 May; 357():j2250. PubMed ID: 28546261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient outcomes in historical comparators compared with randomised-controlled trials.
    Ali M; Jüttler E; Lees KR; Hacke W; Diedler J;
    Int J Stroke; 2010 Feb; 5(1):10-5. PubMed ID: 20088987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
    Latimer NR; Abrams KR; Lambert PC; Morden JP; Crowther MJ
    Stat Methods Med Res; 2018 Mar; 27(3):765-784. PubMed ID: 27114326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.
    Syn NL; Cummings DE; Wang LZ; Lin DJ; Zhao JJ; Loh M; Koh ZJ; Chew CA; Loo YE; Tai BC; Kim G; So JB; Kaplan LM; Dixon JB; Shabbir A
    Lancet; 2021 May; 397(10287):1830-1841. PubMed ID: 33965067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy for randomised clinical trials in rare cancers.
    Tan SB; Dear KB; Bruzzi P; Machin D
    BMJ; 2003 Jul; 327(7405):47-9. PubMed ID: 12842959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
    Royston P; Parmar MK
    Trials; 2014 Aug; 15():314. PubMed ID: 25098243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
    Péron J; Roy P; Ozenne B; Roche L; Buyse M
    JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart Failure with Preserved Ejection Fraction Trials Have Heterogeneous Control Groups: a Comparison of Kaplan-Meier Curves.
    Luo H; Zhang C; Wang J; Zhu J; Jia X
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):577-580. PubMed ID: 30187346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trials. Simple megatrials are not sufficient.
    Barer D
    BMJ; 1999 Apr; 318(7191):1138. PubMed ID: 10213738
    [No Abstract]   [Full Text] [Related]  

  • 13. Life-expectancy projection by modelling and computer simulation (UKPDS 46).
    Stevens R; Adler A; Gray A; Briggs A; Holman R
    Diabetes Res Clin Pract; 2000 Nov; 50 Suppl 3():S5-13. PubMed ID: 11080560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials.
    Kiely BE; Alam M; Blinman P; Tattersall MH; Stockler MR
    Lung Cancer; 2012 Sep; 77(3):537-44. PubMed ID: 22609149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical estimation of life expectancy from large clinical trials: use of left-truncated, right-censored survival analysis methodology.
    Nelson CL; Sun JL; Tsiatis AA; Mark DB
    Stat Med; 2008 Nov; 27(26):5525-55. PubMed ID: 18613251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating treatment effects from a randomized clinical trial in the presence of a secondary treatment.
    Zhang M; Wang Y
    Biostatistics; 2012 Sep; 13(4):625-36. PubMed ID: 22510495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitivity analysis framework for the treatment effect measure used in the meta-analysis of comparative binary data from randomised controlled trials.
    Jackson D; Baker R; Bowden J
    Stat Med; 2013 Mar; 32(6):931-40. PubMed ID: 22941757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analyses of data from randomised trials].
    Skovlund E; Lydersen S
    Tidsskr Nor Laegeforen; 2018 Nov; 138(19):. PubMed ID: 30497239
    [No Abstract]   [Full Text] [Related]  

  • 20. Interpreting treatment effects in randomised trials.
    Guyatt GH; Juniper EF; Walter SD; Griffith LE; Goldstein RS
    BMJ; 1998 Feb; 316(7132):690-3. PubMed ID: 9522799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.